Free to Breathe
2,552 members1,132 posts

FDA grants orphan drug status to an experimental drug for squamous NSCLC

An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here:

You may also like...